Liquid Biopsy Diagnostics is a non-invasive diagnostic technique that uses small molecules found in the bloodstream, such as circulating tumor DNA (ctDNA), cell-free RNA, and other biomarkers, to detect signs of cancer and monitor treatment response.
It addresses the challenges posed by traditional tissue biopsies, which are often painful, expensive, and carry risks such as infection or complications. Liquid biopsies provide a safer, more accessible method to monitor disease progression and treatment response in real-time.
The process involves collecting a blood sample from a patient. The liquid biopsy then analyzes the ctDNA or other relevant markers for specific genetic mutations, methylation patterns, and other indicators associated with cancer. This analysis can identify the presence of cancer at an early stage without the need for invasive tissue biopsies.
The manufacturing process involves developing highly sensitive sequencing technologies capable of detecting trace amounts of ctDNA. This includes optimizing extraction methods for cell-free DNA from blood samples and applying advanced bioinformatics tools to analyze the data accurately.
The build process starts with sample collection, followed by purification and quantification of circulating nucleic acids. Next, these molecules are sequenced using next-generation sequencing (NGS) technologies, and the resulting data is analyzed for specific biomarkers indicative of cancer presence or progression.
Curated names only — none are invented. Use the link to find more.
Cost drivers only — no verified dollar figures are shown. Check live sources for prices.
Illustrative — search real, dated examples rather than trusting a generated story.
Live searches — we don't list papers we can't verify.
Live patent searches — filings are never listed from memory.
Verify against primary sources only.
Source: curated technology intelligence stream with tracked references.